ALBANY, N.Y.--(BUSINESS WIRE)--Nov 19, 2008 - Albany Molecular Research, Inc. (NASDAQ: AMRI) and its wholly owned subsidiary, AMR Technology, Inc., announced that a settlement regarding U.S. patent infringement litigation involving ALLEGRA and
« Pet owners turning to meds to help their critters cope - Prince Edward Island Guardian | Main | [Relapse of small cell carcinoma of the lung with metastasis to iris] »
Verify your Comment
Previewing your Comment
This is only a preview. Your comment has not yet been posted.
Your comment could not be posted. Error type:
Your comment has been posted. Post another comment
As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.
Having trouble reading this image? View an alternate.
Recent Posts
- Solitary plasmacytoma of bone--a rare disorder with an unusual evolution.
- Anti-inflammatory activity of H1-receptor antagonists: review of recent experimental research.
- Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
- Effects of medical or surgical castration on erectile function in an animal model.
- Private prescription costs for sildenafil within the NHS: a telephone survey.
- [Changes in the circadian rhythm of respiratory activity in "depressive" rats as affected by tricyclic antidepressants]
- Effects of cetirizine on the delayed K+ currents in cardiac cells: comparison with terfenadine.
- Release kinetics of liposome-encapsulated ganciclovir after intravitreal injection in rabbits.
- Enteropathy-type T-cell lymphoma showing repeated small bowel rupture and refractoriness to chemotherapy: a case report.
- Eosinophil markers in seasonal allergic rhinitis. Intranasal fluticasone propionate inhibits local and systemic increases during the pollen season.
Comments